Spheramine Titan/Schering
Grosset, D.; Grosset, K.
Current Opinion in Investigational Drugs 6(7): 722-728
2005
ISSN/ISBN: 1472-4472 PMID: 16044669 Document Number: 588271
Spheramine, which is composed of microcarriers coated with dopamine-producing human retinal pigment epithelial cells, is being developed by Titan and Schering for the potential treatment of advanced Parkinson's disease. Phase II trials were ongoing in March 2005 and, at this time, were expected to be completed in the second half of 2006.